Health-related quality of life of adolescents with sickle cell disease in sub-Saharan Africa: a cross-sectional study

David Muthahi Kambasu1*, Joseph Rujumba1, Hervé Monka Lekuya2, Deogratias Munube1,3 and Ezekiel Mupere1

Abstract

Background: Sickle cell disease (SCD) is a chronic hematologic disease associated with increased morbidity and mortality. Hemoglobinopathies are the most prevalent genetic disease globally, and SCD is estimated to affect 0.7% of Ugandan. The disease may adversely impact on the quality of life of sickle cell patients. This study aimed to evaluate the health related quality of life (HRoL) of adolescents with SCD.

Methods: This was a mixed-methods study of adolescents with sickle cell disease and their caretakers living in Kampala city, Uganda. All children aged 8–17 years with homozygous sickle cell disease attending the sickle cell clinic at Mulago Hospital during the study period were included in this study. Participants completed the PedsQL™ generic core scales parent-proxy and child self-report questionnaire during a routine clinic visit. HRQoL was the primary outcome measured. Socio-demographics and disease related data were obtained through personal interview with caretakers and reviewing patients’ medical records. Mean scores were used for HRQoL and linear regression for associated factors.

Results: Of the 140 adolescents with SCD included in the study, 40% were male. A total of 95 adolescents (68%) were between the age of 8–12 years with a mean age of 14.25 years. The physical function was assessed slightly higher by adolescents with a mean score of 57.5 ± 20.3 compare to caretakers with 52.8 ± 22.1 (p < 0.001). As assessed by caretakers, physical HRQoL scores were negatively associated with pain about 10.02 CI [−19.22, −0.81] (p = 0.033), whereas it was positively associated with Pneumococcal vaccine with the score of 28.43 CI [16.78, 40.09] (p < 0.001) as assessed by adolescents and 31.37 CI [22.22, 40.51] (p < 0.001) by caretakers. Pneumococcal vaccination impacted positively the psychosocial functioning with a score of 8.67 CI [1.51, 15.84] (p = 0.018) as assessed by children and 15.94 CI [5.50, 26.38] (p = 0.003) as assessed by the caretakers.

Conclusions: This study highlighted that pain was negatively associated with both physical and psychosocial functioning; whereas getting Pneumococcal vaccine was positively associated with both physical and psychosocial functioning as reported by children and caretakers.

Keywords: Sickle cell disease, Quality of life, PaedsQL, Pneumococcal vaccine, Caretaker, Sub-Saharan Africa
Background
Sickle cell disease (SCD) is a group of inherited red blood cell disorders characterized by the presence of abnormal hemoglobin where there is a substitution of hydrophilic glutamic acid by hydrophobic Valine at position 6 of beta-globin chain. The clinical manifestations are diverse and may include vaso-occlusive, hematological and infectious crisis. Sickle cell disease is a serious global health issue with an estimated 400,000 neonates born with the disease each year and about 300,000 of these with sickle cell anemia [1]. The greatest burden is seen in sub-Sahara Africa where more than 75% of all sickle cell disease occurs; this proportion is projected to increase by 2050 [1]. In Uganda, the overall number of children with sickle cell trait is 13.3% and with disease is 0.7% having SCD [1].

Health Related Quality of life (HRQoL) is defined as an extent to which one's usual or expected physical, emotion and social well-being is affected by a medical condition or its treatment [2]. Previous study found a lower HRQoL to patients with SCD compared to the general adult's population [3]. In that study, a lower HRQoL was found in several domains by children with SCD and their parents [3, 4].

A number of disease-related factors have been found to affect quality of life (QoL) in children with SCD such as vulnerable socioeconomic status, age of the patient by physical manifestations of SCD notably in the form of abnormal sexual and physical development, type of pathology, family support, beliefs and values [5]. The clinical conditions such as pain, fever, skin redness, swelling, and history of blood transfusion are significant predictors of lower HRQoL in children with sickle cell disease [5]. Swelling has been documented to negatively affect to physical function, vitality, social function, bodily pain, and general health [5].

This study represents the first investigation of SCD patients’ QoL of adolescent population in Uganda. We hypothesized that SCD in adolescents was associated with low HRQoL and demographic and disease factors might have an impact on HRQoL. In this study we aimed to describe the health-related QoL of adolescents with SCD, and examine explanatory predictors that might be associated with QoL.

Methods
Study design, population and site
The present study used a mixed-methods study design with quantitative and qualitative methods that included adolescents with SCD and their caretakers, randomly selected from the Outpatient sickle cell clinic at Mulago National Referral Hospital in Kampala, Uganda from February to April 2018. The study sample consisted of children with SCD aged 8–17 years and their caretakers.

Inclusion criteria: All children aged 8–17 years with homozygous sickle cell disease attending the sickle cell clinic at Mulago Hospital during the study period. Exclusion criteria were: a history of a previous chronic disease (like cancer tuberculosis, HIV); any concomitant serious medical problems (other than those secondary to SCD). A consecutive sampling was done. This process was continued until sample size was reached. Many of our participants were visiting for acute pain and few were in their usual state of health.

Variables measurement
The socio-demographic and disease characteristics
An interviewer administered questionnaire was used to obtain information on the participants and the caregiver's socio-demographic characteristics (age, gender, date of birth, relationship with child, education, residence and household income) and history of blood transfusion for the last one year. Physical examination findings such as vital signs (temperature, pulse rate, respiratory rate, and oxygen saturation), presence or absence of complications of the disease, such as infection, dehydration and pain, were recorded. The time period reviewed for pain and fever was information within the 30 days. Fever was defined as axillary temperature equal or more than 38 C (101.3 F). Pain: constant cry restlessness, facial expression and verbal report of pain. Anthropometric measurements were taken. Malaria (positive blood slide), hemoglobin electrophoresis, treatment such as Hydroxyurea, Folic acid and Pneumococcal vaccine were obtained by reviewing patients' medical records.

Evaluation of health quality of life
The acute version of pediatric quality of life questionnaire with 7 days recall was separately administered to parent proxy and children by the research assistant to determine Health Related Quality of Life [6]. The PedsQL™ Generic Core has four domains: physical, emotional, social and school functioning, with child self-report versions for a broad age range (age groups 5–7, 8–12, and 13–18) and parallel parent proxy reports for each age group. The Pediatric quality of life inventory is composed of 23 items comprising 4 dimensions. Higher scores in the inventory indicate better health related quality of life. In this study a 5 point scale was used with scores ranging from 0 (never) to 4 (almost always). Likert response scale items are reverse-scored and linearly transformed to a 0–100 scale (0 = 100, 1 = 75, 2 = 50, 3 = 25, 4 = 0), so that higher PedsQL™ scores indicate better HRQoL [7, 8]. The established cut-off scores meaning poor quality of life by using PedsQL™ generic instrument were 69.7 for child self-report and 65.4 for parental proxy report in comparison with general
population \[9\]. The English version was translated by the research assistant.

**Qualitative methods of data collection**
Qualitative data were collected using focus group discussions (FGDs) with adolescents and caretakers. Two FGDs discussions were conducted with children and 2 FGDs with their caretakers/parents. For each category one FGD was with those who assessed low quality of life and another one with those who assessed high quality of life for children with SCD. Each FGD had 7–10 participants.

**Statistical analyses**
The quantitative data were entered into Epidata version 3.1 and exported to STATA for analysis. For the qualitative component, audio recorded discussions were transcribed and analyzed manually using content thematic approach which involved grouping data according to study themes and sub-themes with guidance from the qualitative researcher on the team. Direct quotations from study participants were used in the presentation of the study findings.

Descriptive statistics such as means and standard deviation (mean ± SD) were used to describe the quantitative variables. Frequencies (N) and percentages (%) were used to describe categorical variables. At univariate and multivariate analysis stage a multiple linear regression model was fit with HRQoL as the dependent variables and only independent variables with \(p\)-values \(< 0.05\) were considered as the significantly associated factors. In multiple linear regression analyses, \(p < 0.05\) was considered significant.

**Table 1** Socio-demographic of adolescents with SCD and their caretakers

| Variables          | Adolescents with SCD Frequency(N=140) | Percent | Caretakers of adolescents with SCD Frequency(N=140) | Percent |
|--------------------|----------------------------------------|---------|-----------------------------------------------------|---------|
| Gender             |                                        |         | Gender                                              |         |
| Male               | 56                                     | 40      | Male                                                | 12      |
| Female             | 84                                     | 60      | Female                                              | 128     |
| Age group          |                                        |         | Age group                                           |         |
| 8-12               | 95                                     | 68      | <35                                                 | 66      |
| >=12               | 45                                     | 32      | >=35                                                | 74      |
| Relationship with child |                                   |         | Income level\(^a\)                                  |         |
| Mother             | 122                                    | 87      | <=57 $                                              | 113     |
| Other              | 18                                     | 13      | >57 $                                               | 22      |
| Marital status     |                                        |         | Marital status                                     |         |
| Married            | -                                      | -       | Married                                             | 124     |
| Single             | -                                      | -       | Single                                              | 16      |

\(^a\) Some missing variables for income level

**Ethical considerations**
Ethical approval was obtained from Makerere University College of Health Sciences, School of Medicine Research and Ethics Committee and the National Council for Science and Technology. Informed consent for data collection and publication was obtained from parents/ caretakers, and informed assent from children.

**Results**

**Demographic and disease factors**
Of the 140 children with SCD included in the study who were all homozygous SS, 40% were male. A total of 95 children (68%) were between the ages of 8–12 years (Table 1), mean age was 14.25 years. Among the caretakers, 53% were above 35 years of age, 91% were female, and 113(84%) had income level of less than 57$ per month. The majority of the children 91/140(65%) came to the hospital with fever and 89/140 (64%) came with pain. Only 35% are on Hydroxyurea, 131(95%) are taking folic acid and 26% have gotten Pneumococcal vaccine. Only 3% got more than 3 blood transfusions in the last one year. Further details of study participants are presented in Table 2.

**The mean HRQoL**
As shown in Table 3, the mean score of physical, emotional school and psychosocial functioning were below the recommended cut off as assessed by adolescents. However, social functioning was high as assessed by both adolescents and caretakers but it was not statistically significant. The HRQoL was lower in female in emotional functioning \(p<0.0005\), and social functioning \(p<0.007\) Table 4. Adolescents on pain reported their HRQoL as low in school functioning with \(p<0.003\). The HRQoL was reported high by adolescents taking Hydroxyurea in all
domains though it was only significant in physical functioning with a p<0.001. Adolescents having experienced stroke, reported their HRQoL as low but it was not significant in school functioning ($p=0.12$) and physical functioning ($p=0.14$) Table 4.

**Disease factors and HRQoL**

We found that a change of one unit from not receiving Pneumococcal vaccine to receiving it increases the physical functioning by 28 and 31 points ($p<0.001$) in both adolescents and caretakers respectively. Having gotten more than 3 blood transfusions impacted positively on the physical functioning as assessed by adolescents and caretakers ($p=0.002$) at multivariate analysis (Table 5).

It was found that Hydroxyurea, pain, stroke, and more than 3 blood transfusions impacted negatively on the psychosocial functioning as assessed by both adolescents and their caretakers. However, Pneumococcal vaccination and history of 1–3 blood transfusions had a positive impact on psychosocial functioning (Table 6).

**Qualitative result**

With regard to qualitative results, all adolescents and their caretakers in group discussions mentioned missing school due to frequent pain and hospital visits which translated into poor school performance as key factors negatively affecting the HRQoL for adolescents with SCD. Many adolescents talked about how their academic performance had declined due to SCD as they explained:

"When you look at the academic side my performance is affected because I get attacks during examinations and the performance is poor because the society does not look into us as a special case to give special examinations" (FGD adolescents with low HRQoL).

"Pain and coming to the hospital for care stops me from going to school..." (FGD adolescents with low HRQoL).

Most of the adolescents and their caretakers reported stigma to be a major factor affecting HRQoL for adolescents with SCD. Some adolescents felt they had been stigmatized on the basis of how they looked due to SCD and were often excluded from playing with other children as one of them explained: “For me children at school abuse me. They say that I have eyes like for a wild cat because they are yellow. They tell me that they can’t

---

**Table 2** Disease characteristics of adolescents with SCD

| Variables      | Frequency (N=140) | Percent | Variables      | Frequency (N=140) | Percent |
|----------------|-------------------|---------|----------------|-------------------|---------|
| Fever          |                   |         | Hydroxyurea*   |                   |         |
| Yes            | 91                | 65      | Yes            | 45                | 35      |
| Non            | 49                | 35      | Non            | 84                | 65      |
| Malaria*       |                   |         | Folic acid*    |                   |         |
| Yes            | 13                | 10      | Yes            | 131               | 95      |
| Non            | 123               | 90      | Non            | 7                 | 5       |
| Pain           |                   |         | Pneumococcal*  |                   |         |
| Yes            | 89                | 64      | Yes            | 36                | 26      |
| Non            | 51                | 36      | Non            | 101               | 74      |
| Stroke         |                   |         | Blood transfusion |               |         |
| Yes            | 20                | 14      | None           | 117               | 84      |
| Non            | 120               | 86      | 1-3            | 20                | 14      |
| >3             | 3                 | 2       |                |                   |         |

*aSome missing variables for income level, malaria, Hydroxyurea, Folic acid and Pneumococcal vaccine*

---

**Table 3** Mean score of PedsQLTM of adolescents with SCD as assessed by adolescents and caretakers

| Variables      | N  | Child Means(±SD) | N  | Caretaker Means(±SD) | Mean Diff. | p      |
|----------------|----|------------------|----|----------------------|------------|--------|
| Total score    | 140| 62.98(14.5)      | 140| 63.24(15.9)          | −0.26      | 0.667  |
| Physical functioning | 140| 57.5 (20.3)      | 121| 52.8 (22.1)          | 4.7        | < 0.001|
| Emotional functioning | 140| 61.4 (19.0)      | 121| 67.2 (20.9)          | −5.8       | 0.003  |
| Social functioning    | 140| 74.6 (21.5)      | 121| 73.4 (24.4)          | 1.2        | 0.7609 |
| School functioning      | 140| 58.4 (19.9)      | 121| 59.7 (22.5)          | −1.3       | 0.7586 |
| Psychosocial HRQoL      | 140| 64.8 (15.9)      | 121| 67.0 (18.6)          | −1.2       | 0.1216 |

*Psychosocial HRQoL: includes sum of Emotional, Social and School functioning*
play with me because they don’t want to associate with sicklers. This makes me feel bad and I cry” (FGD with adolescents with low HRQoL).

Another adolescent added: “Even me they don’t like me at school. They say that I should take away my sickle cell yet when they want to learn something they come and ask me but for me I tell them the answers but even in class I perform better than them” (FGD caretakers of adolescents with low HRQoL).

Most adolescents reported that SCD limits them from taking part in community and household activities as well as play which negatively affected their quality of life.

“For me I can’t participate in sports yet I like football, I do not participate in sports and games because I cannot compete with other children so we lose our skill and yet we always love our hobbies” (FGD adolescents with low HRQoL).

“For me I can’t do heavy work because I am weak. Sometimes I faint and my mother doesn’t allow me to carry heavy things. When I do heavy work I start feeling pain and sometimes they end up bringing me to the hospital” (FGD adolescents with low HRQoL).

Discussion
SCD has been widely researched on in sub-Saharan Africa, but there is a paucity of studies on the impact of the disease on the school, emotional, physical, and social well-being of the patients despite the high prevalence of SCD in sub-Saharan Africa. In this study, we found that the HRQoL was low in physical functioning, emotional functioning and school functioning as assessed by adolescents, and was also low in physical functioning and school functioning as assessed by the caretakers.

The physical and emotional functioning are lower than the study done by Joanita et al. [10]; this could be

| Table 4 | Mean score of HRQoL, demographic and disease factors as reported by adolescents |
|---------|--------------------------------------------------------------------------------|
| Variables | PhF (±SD) | EmF (±SD) | SocF (±SD) | SchF (±SD) | PsyF (±SD) |
| Age group(child) | |
| > 12 | 57.8 ± 20.13 | 0.9018 | 67.6 ± 16.36 | 0.0079 | 78.7 ± 18.73 | 0.1258 | 60.6 ± 14.93 | 0.3065 | 68.9 ± 16.31 | 0.0348 |
| ≤ 12 | 57.3 ± 20.52 | 0.8581 | 58.5 ± 19.98 | 0.0189 | 72.7 ± 22.57 | 0.2770 | 57.4 ± 17.71 | 0.3065 | 62.9 ± 14.37 |
| Gender (child) | |
| Male | 57.7 ± 21.85 | 0.9094 | 68.1 ± 21.01 | 0.0005 | 80.6 ± 17.58 | 0.0070 | 58.3 ± 19.05 | 0.0433 | 69.0 ± 16.76 | 0.0105 |
| Female | 57.3 ± 19.78 | 0.6578 | 56.9 ± 16.22 | 0.0189 | 70.7 ± 23.05 | 0.0178 | 58.5 ± 15.38 | 0.0178 | 62.0 ± 14.77 |
| Fever Means (±SD) | |
| No | 54.9 ± 13.19 | 0.2711 | 65.9 ± 21.23 | 0.0385 | 77.4 ± 2.17 | 0.2770 | 56.8 ± 14.17 | 0.4149 | 66.7 ± 14.87 | 0.3070 |
| Yes | 58.7 ± 23.23 | 0.9018 | 59.0 ± 17.38 | 0.0385 | 73.1 ± 24.53 | 0.9018 | 59.3 ± 18.19 | 0.9018 | 63.8 ± 16.44 |
| Pain | |
| No | 61.5 ± 22.3 | 0.0735 | 59.2 ± 20.70 | 0.0307 | 74.8 ± 22.53 | 0.9227 | 56.1 ± 15.18 | 0.0003 | 64.8 ± 15.44 | 0.3771 |
| Yes | 55.1 ± 18.83 | 0.5678 | 62.64 ± 18.01 | 0.4765 | 74.5 ± 21.07 | 0.4765 | 54.6 ± 16.69 | 0.4765 | 63.9 ± 16.19 |
| Malaria Means (±SD) | |
| No | 57.7 ± 21.1 | 0.2940 | 59.7 ± 15.53 | < 0.001 | 73.6 ± 20.84 | 0.0003 | 56.6 ± 16.8 | < 0.001 | 63.3 ± 14.21 | < 0.001 |
| Yes | 63.7 ± 8.2 | 0.2940 | 88.5 ± 21.92 | 0.9018 | 95.4 ± 8.77 | 0.9018 | 75.4 ± 8.77 | 0.9018 | 86.4 ± 13.16 |
| Hydroxyurea Means (±SD) | |
| No | 53.6 ± 18.95 | < 0.001 | 59.5 ± 21.56 | 0.1179 | 73.0 ± 24.61 | 0.2394 | 56.6 ± 17.48 | 0.1182 | 63.1 ± 18.15 | 0.0866 |
| Yes | 69.5 ± 17.86 | 0.2940 | 65.33 ± 15.09 | 0.1179 | 77.6 ± 12.86 | 0.1179 | 61.7 ± 17.29 | 0.1179 | 68.2 ± 11.20 |
| Folic acid Means (±SD) | |
| No | 71.5 ± 0.17 | 0.6038 | 59.3 ± 1.89 | 0.7564 | 78.6 ± 9.45 | 0.6038 | 62.9 ± 7.56 | 0.4634 | 66.9 ± 5.04 | 0.7127 |
| Yes | 56.9 ± 20.45 | 0.2940 | 61.6 ± 19.65 | 0.4726 | 74.2 ± 22.06 | 0.4726 | 58.0 ± 17.28 | 0.4726 | 64.6 ± 16.39 |
| Pneumococcal vaccine Means (±SD) | |
| No | 56.7 ± 17.84 | 0.4348 | 58.3 ± 20.93 | 0.0011 | 72.3 ± 23.91 | 0.0586 | 59.0 ± 18.96 | 0.4628 | 63.2 ± 17.97 | 0.0608 |
| Yes | 59.9 ± 20.54 | 0.2940 | 70.3 ± 8.53 | 0.0011 | 80.3 ± 12.07 | 0.0586 | 56.5 ± 9.47 | 0.6038 | 69.0 ± 7.39 |
| Stroke Means (±SD) | |
| No | 58.5 ± 21.13 | 0.1401 | 63.7 ± 17.05 | 0.0004 | 76.1 ± 20.47 | 0.0441 | 59.3 ± 16.33 | 0.1207 | 66.4 ± 14.86 | 0.0042 |
| Yes | 51.3 ± 13.39 | 0.1401 | 47.8 ± 24.52 | 0.1401 | 65.7 ± 25.83 | 0.1401 | 52.0 ± 19.43 | 0.1401 | 55.5 ± 19.04 |
explained by the fact that their study was conducted in a higher income country, where by children with SDC are likely to have better care. This finding can also be explained by cultural differences where level of social support, coping style and perception of illness are different as compared to the developed countries.

Qualitative results also indicated that SCD affects negatively school functioning. In addition most of the study participants in FGDs reported stigma to be a factor affecting their emotional HRQoL. Most adolescents reported having a problems with their physical functioning such as in the form of being unable to play and do home activities due to SCD and related complications.

Our findings on low HRQoL among children with SCD are consistent with those of previous studies [11–13]. The study done by Mohammad and Kamfar regarding the association between disease severity, depression, social support, and the combined and/or singular effect on HRQoL in children with SCD, found a significant impairment of QOL in all domains among children with SCD [14].

Panepinto et al. used the PedsQL™ 4.0 and concluded an impaired HRQoL in children with SCD, even after considering the potential effect of family income on HRQoL. In another study, Dale et al. found an overall HRQoL lower in children with SCD and their parent than in healthy children and their parents, a finding that matched our results [15].

Gender influences HRQoL of adolescents with SCD. A previous study using the Child Health Questionnaire found that children reported statistically significant gender differences in HRQoL with diminished scores on most functioning scales for female subjects [16]. Gender differences in pain have been described; the frequency of pain is higher among female [17].

Adolescents with SCD who are taking Hydroxyurea therapy report better physical functioning than those not taking the medication. This is consistent with the study

### Table 5: Disease factors and physical HRQoL of adolescents with SCD at multivariate regression analysis (adolescents and caretakers report)

| Variables                | Adolescents’ response | P       | Caretakers’ response | p       |
|--------------------------|-----------------------|---------|----------------------|---------|
|                          | Estimate (95% CI)     |         |                      |         |
| Malaria                  |                       |         |                      |         |
| No                       | 1.00                  |         | 1.00                 |         |
| Yes                      | 32.39(20.14, 44.63)   | <0.001  | 37.05(27.95, 41.14)  | <0.001  |
| Hydroxyurea              |                       |         |                      |         |
| No                       | 1.00                  |         | 1.00                 |         |
| Yes                      | −0.84 (−10.98, 9.29)  | 0.869   | 5.30 (−5.59, 16.20)  | 0.336   |
| Folic acid               |                       |         |                      |         |
| No                       | 1.00                  |         | 1.00                 |         |
| Yes                      | −28.76 (−45.41, −12.10) | 0.001  | −46.17 (−65.96, −26.39) | <0.001  |
| Pneumococcal vaccine     |                       |         |                      |         |
| No                       | 1.00                  |         | 1.00                 |         |
| Yes                      | 28.43 (16.78, 40.09)  | <0.001  | 31.37 (22.22, 40.51) | <0.001  |
| Pain                     |                       |         |                      |         |
| No                       | 1.00                  |         | 1.00                 |         |
| Yes                      | −4.70 (−14.35, 4.95)  | 0.336   | −10.02 (−19.22, −0.81) | 0.033   |
| Fever                    |                       |         |                      |         |
| No                       | 1.00                  |         | 1.00                 |         |
| Yes                      | 24.39 (15.03, 33.74)  | <0.001  | 30.67 (23.5, 37.84)  | <0.001  |
| Stroke                   |                       |         |                      |         |
| No                       | 1.00                  |         | 1.00                 |         |
| Yes                      | 9.15 (−0.75, 19.05)   | 0.070   | −29.34 (−40.69, 18.59) | <0.001  |
| Blood transfusion        |                       |         |                      |         |
| None                     | 1.00                  |         | 1.00                 |         |
| 1–3                      | 6.63 (−6.60, 19.86)   | 0.323   | 3.48 (−8.40, 15.36)  | 0.562   |
| > 3                      | 31.17 (11.62, 50.72)  | 0.002   | 24.03 (8.83, 39.23)  | 0.002   |
done by Coutney D. et al were they found a better physical functioning in children taking Hydroxyurea [18]. The study done by S. M. Badawy et al, showed that patients on Hydroxyurea with no recall barriers had better HRQoL [19]. This is because of the impact of a disease modifying therapy (Hydroxyurea) on the HRQL of children with SCD. It is well known that Hydroxyurea therapy decreases the frequency of vaso-occlusive episodes.

Stroke influence the HRQoL of adolescents with sickle cell disease. The study done by Chia Yeh Chou also found that, the psychosocial and physical factors impacted stroke-specific HRQoL [20]. The characteristics of individual patients, their social environment, the specific type of care provided and the experience of disability are factors that influence the impact of stroke on the HRQoL level. The predictors of poor QoL post-stroke include: depression, medical comorbidities, functional status and perceived social support [21].

Adolescents in pain rated their HRQoL as low in school functioning. Anie found that pain experience accounted for 12.3% of hospital and general practice service use, independently of age, sex, number of SCD complications and hemoglobin levels [22]. We found also that pain impacted negatively on the physical and psychosocial HRQoL. This is in consistence with the study done by Carlton et al. where they found that pain negatively influenced child reports on almost all functioning [23]. In our study children narrated how pain limited them from attending school as well as participating in play activities which negatively affected their quality of life. Ludwig et al. found that executive functioning is an important factor in understanding the relationship between pain coping and HRQoL in youth with SCD [24].

A study done in US by S. K. Ballas et al. found pain as a predictor of quality of life QoL outcomes, in physical and social functioning [25]. Another study found an impaired QoL in patients with acute and chronic pain more than any other disease-related complication [26].

At multivariate analysis in this study, more than 3 blood transfusions were associated with increase in physical functioning of adolescents with SCD (Table 5). Reducing anemia by giving blood transfusion, painful crisis will reduce, thus improving the HRQoL. This finding is in agreement with the findings of a randomized trial study done by Laurent et al. where blood transfusion was found to improve health among children with SCD. The parents reported that their transfused children had better physical health functioning a year later [27]. With regard to psychosocial functioning, the blood transfusion was assessed by adolescents and their caretakers to have a negative influence on adolescent’s quality of life. This might be due to the painful procedures that traumatize children when getting blood transfusion, though it physically helps them.

| Table 6 Disease factors and psychosocial HRQoL of adolescents with SCD at multivariate regression analysis (adolescents and caretakers report) |
| Variables                      | Psychosocial HRQoL | p       | Caretakers’ response | p       |
| Malaria                        | adolescents’ response Estimate (95% CI) | p       | Caretakers’ response Estimate (95% CI) | p       |
| Yes                            | 38.74(31.21,46.30) | < 0.001 | 17.39(7.00,27.77) | < 0.001 |
| Hydroxyurea                    | Yes               | −12.57(−18.80,−6.34) | < 0.001 | −29.165(−41.35,−16.98) | < 0.001 |
| Folic acid                     | Yes               | 1.27(−8.97,11.51) | 0.806 | −11.62(−33.63,10.38) | 0.296 |
| Pneumococcal vaccine           | Yes               | 8.67(1.51,15.84) | 0.018 | 15.94(5.50,26.38) | 0.003 |
| Pain                           | Yes               | −4.37(−10.30,1.56) | 0.147 | −29.17(−39.39,−18.94) | < 0.001 |
| Fever                          | Yes               | 16.06(10.30,21.01) | < 0.001 | 4.53(−3.48,12.56) | 0.264 |
| Stroke                         | Yes               | −6.78(−12.87,−0.70) | 0.029 | −29.34(−40.69,18.59) | < 0.001 |
| Blood transfusion              | 1–3               | 13.89(5.76,22.03) | 0.001 | −26.46(−40.00,12.91) | < 0.001 |
|                               | > 3               | −28.28(−40.30,−16.26) | < 0.001 | −62.63(−79.52,45.74) | < 0.001 |
It was found in this study that Hydroxyurea influenced positively the physical functioning as reported by caretakers; but it was not statistically significant. Treatment of SCD patients with Hydroxyurea improves their clinical and hematological characteristics. Thornburg et al. in Carolina also found that Children with SCD who were taking Hydroxyurea therapy reported better physical functioning and overall HRQoL than those not taking the medication despite disease severity and older age [28]. Tshilolo et al. found that Hydroxyurea used reduced the incidence of vaso-occlusive events, infections, malaria, transfusion and death [29]. In the study done by McClish et al. data showed that Hydroxyurea can also improve some measures of QoL including general health perception and pain recall. The effect was especially evident in patients with sustained HbF (fetal hemoglobin) response to Hydroxyurea.

With regard to psychosocial functioning, we found a negative impact of Hydroxyurea on psychosocial domain with a $p < 0.001$ as assessed by adolescents and caretakers. The study done by Thornburg et al. in Carolina found no differences between groups of patients on Hydroxyurea and those not on Hydroxyurea in the psychosocial summary score or its individual domains [28]. The lack of demonstrable effect of Hydroxyurea on certain QoL measures may be the result of issues inherent in patients with moderate to severe disease who were already debilitated and had irreversible effects of their disease or poor adherence to drug; Sherif et al. found that female had worse QoL score and were poorly adhered to Hydroxyurea [30]. In the study done by Badawy et al. it was found that beliefs about Hydroxyurea correlated with HRQoL score and adherence [31]. In the qualitative part of the study, children reported difficulties in adhering to daily drugs which negatively affected their quality of life. It is important to consider also the effect of Hydroxyurea in increasing HbF as found by the study done by McClish et al. [32].

Pneumococcal vaccination was associated with increase in physical functioning and psychosocial functioning as assessed by both adolescents and their caretakers (Tables 5 and 6). Pneumococcal vaccine reduces the frequency of bacterial infections thus improving the HRQoL for children with SCD [33].

In a study done by Gayatri et al. concerning initial outcomes of a comprehensive care model for sickle cell disease among a tribal population in rural western India there was a reduction in the proportion of patients with ≥3 pain crises per year (35.4 to 9.8%, $p < 0.001$) and the proportion of patients with ≥1 hospitalization per year (56.7 go 36.0%, $p < 0.001$) in patients who got Pneumococcal vaccine and Hydroxyurea [34].

Limitation of the study
In this study, we enrolled patients who were only in the Sickle clinics of the Mulago National Referral Hospital, Kampala, Uganda, which may have resulted in a bias towards enrolling patients who are severely sick. We extracted data on some variables from clinic records some of which had missing values. We did a consecutive sampling. This process was continued until sample size was reached; many of our participants were visiting for acute pain and few were in their usual state of health. That might have impacted HRQoL. We also had lack of qualitative validation of the translated version.

Conclusion
This study was done to assess the HRQoL of adolescents with SCD as assessed by adolescents and their caretakers. We found that adolescents with SCD have low HRQoL as assessed by participants. The mean physical, emotional, school and psychosocial functioning were below the cut-off as assessed by adolescents with SCD.

We found also that Pneumococcal vaccination and getting more than 3 blood transfusions were positively associated with physical functioning. Taking Hydroxyurea, having stroke and getting more than 3 blood transfusions negatively influenced the psychosocial functioning of adolescents with SCD. Adolescents with SCD experienced regular pain, problems with growth, stigma and missed school which negatively affected their HRQoL. We recommend further studies with long term prospective to identifying causal association of above reported factors.

Abbreviations
- $5$: United States dollar; FGD: Focus group discussions; HbF: Fetal hemoglobin; HRQoL: Health-related quality of life; PedsQL™: Pediatric Quality of Life Inventory; QoL: Quality of life; SCD: Sickle cell disease

Acknowledgements
The authors would like to thank all the pediatricians in the department of Pediatrics and Child Health for their support. The authors extend their sincere appreciation to the respondents for their participation in this study. The authors also acknowledge the efforts of sisters Kasiye and Hanriet who have been involved in collecting the data for this study.

Funding
This work was supported by Oicha Referral Hospital, Ministry of health, Democratic Republic of Congo and the NGO “Les Amis du Nord/Kivu” based in Belgium. The funders had no role in the research process.

Availability of data and materials
Data sets are available by a friendly request to the corresponding author.

Authors’ contributions
DMK involved in the design of the study, conducted the statistical analysis, and wrote the manuscript. JR involved in the design of the study and helped edit the manuscript. EM, HML and DM participated in the manuscript redaction and coordination of the study. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Ethical approval was obtained on the 22 February 2018 with the code of: REC-REF. 2018-032, from Makerere University College of Health Sciences, School of Medicine Research and Ethics Committee and the National Council for Science and Technology. A written informed consent was obtained from parents/caretakers, and a written informed assent from children. Confidentiality was maintained by use of study IDs and all study documents was kept under lock and key in safe secure waterproof cabinet.

Consent for publication
All participants have consented for publication of the result of this study (medical information, quotes and images). This was a written consent which was obtained during the same time of consent to participate. The parents consented for minor adolescents and an assent was obtained for adolescents.

Competing interests
The authors declared they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1 Pediatrics and Child Health, School of Medicine, College of Health Sciences Makerere University, Kampala, Uganda. 2 Department of Surgery, College of Health Sciences Makerere University, Kampala, Uganda. 3 Mulago National Referral Hospital, Kampala, Uganda.

Received: 13 December 2018 Accepted: 22 April 2019
Published online: 14 May 2019

References
1. Ndeegi GKC, Hernandez AG, Munube D, Howard TA, Ssewanyana I, Nsungwa J, Kiguli S, Ntugwa CM, Waie RE, Aceng JR. Burden of sickle cell trait and disease in the Uganda Sickle Surveillance Study (US3): a cross-sectional study. Lancet Glob health. 2016. https://doi.org/10.1016/S2214-109X(15)00288-0.
2. Cell DF. Measuring quality of life in palliative care. In: Seminars in oncology; 1995; 1995. p. 73–81.
3. Dampier C, Lief S, LeBeau P, Rhee S, McMurray M, Rogers Z, Smith-Whitney K, Wang W. Health-related quality of life in children with sickle cell disease: a report from the comprehensive sickle cell centers clinical trial consortium. Pediatr Blood Cancer. 2010;55(3):485–94.
4. Panepinto JA, Bonner M. Health related quality of Life in sickle cell disease: past, present and future. Pediatr Blood Cancer. 2012;59(2):377–85.
5. Ahmed EA, Alaskan AS, Al-Sulaman AM, Jazheir A-R, McClure DK, Ali Sabram M, Ali YZ, Mulhan H, Mendoza MA, Gorashi AO. Health-related quality of life in patients with sickle cell disease in Saudi Arabia. Health Qual Life Outcomes. 2015;13(1):183.
6. Brandow AM, Broussard DC, Pajewski NW, Panepinto JA. Vaso-occlusive painful events in sickle cell disease: impact on child well-being. Pediatr Blood Cancer. 2010;54(9):2–7.
7. Varni JW, Burwinkle TM, Seid M. The PedsQL TM 4.0 as a school population health measure: feasibility, reliability, and validity. Qual Life Res. 2006;15(2):203–15.
8. Varni JW, Burwinkle TM, Seid M, Skarr D. The PedsQL™ 4.0 as a pediatric population health measure: feasibility, reliability, and validity. Ambul Pediatr. 2003;3(6):329–41.
9. Varni JW, Linner C, Burwinkle TM. Health –related quality of Life measurement in pediatric oncology. Hearing the voice of the children. J Pediatr Psychol. 2007;32(9):1152–63.
10. Dale JC, Cochran CJ, Roy L, Jernigan E, Buchanan GR. Buchanan, Health-related Quality of Life in Children and Adolescents With Sickle Cell Disease. J Pediatrics Health Care. 2011;25(4):208–215.
11. Wethers D. Sickle cell disease in childhood: part II. Diagnosis and treatment of major complications and recent advances in treatment. Am Fam Physician. 2000;62:1309–14.
12. Ramsey LT, Woods KD, Callahan LA, Menash GA, Barbeau P, Gutin B. Quality of life improvement for patients with sickle cell disease. Am J Hematol. 2001;66:155–6.
13. Palermo TM, Schwartz L, Drotar D, McGowan K. Parental report of Health-related quality of life in children with sickle cell disease. J Behav Med. 2002;25:269–83.
14. Sehlo MG, Kamfar HZ. Depression and quality of life in children with sickle cell disease: the effect of social support. BMC Psychiatry. 2015;15:78. https://doi.org/10.1186/s12888-015-0461-6.
15. Dale JC, Cochran CJ, Roy L, Jernigan E, Buchanan GR. Health-related quality of life in children and adolescents with sickle cell disease. J Pediatr Health Care. 2011;25(4):208–15.
16. Varni JW, Burwinkle TM, Seid M, et al. The PedsQL 4.0 as a pediatric measure: feasibility, reliability, and validity. Ambul Pediatr. 2003;3:329–41.
17. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med. 1991;325:11–6.
18. Thomburg CD, Calatoni A, Panepinto JA. Differences in health related quality of life in children with sickle cell disease receiving hydroxyurea. J Pediatr Hemat Oncol. 2013. https://doi.org/10.1097/MPH.0b013e3182114c54.
19. Badawy SM, Thompson AA, Penedo FJ, Lai JS, Rycklik K, Liem R. Barriers to hydroxyurea adherence and health-related quality of life in adolescents and young adults with sickle cell disease. Eur J Haematol. 2017;98(6):608–14.
20. Chou CY. Determinants of the Health-related Quality of Life for Stroke Survivors. J Stroke Cerebrovasc Dis. 2015. https://doi.org/10.1016/j.jsct.2015.04.022.
21. Paul SL, Sturm JW, Dewey HM, Donnan GA, Macdonell RA, Thrift AG. Long-term outcome in the north East Melbourne stroke incidence study: predictors of quality of life at 5 years after stroke. Stroke. 2005;36(10):2082–6.
22. Anie KA, Stepece A, Bevan DH. Sickle cell disease: Pain, coping and quality of life in a study of adults in the UK. Bri J Health Psychol. 2002;7:331.
23. Dampier C, Lief S, LeBeau P, Rhee S, McMurray M, Rogers Z, Smith-Whitney K, Wang W. Health-related quality of life in children with sickle cell disease: a report from the comprehensive sickle cell centers clinical trial consortium. Pediatr Blood Cancer. 2010;55(3):485–94. https://doi.org/10.1002/hj1.22497.
24. Ludwig NN, Sil S, Khowaja MK, Cohen LL, Dampier C. Executive functioning mediates the relationship between pain coping and quality of life in youth with sickle cell disease. J Pediatr Psychol. 2018. https://doi.org/10.1093/jpepsy/jsy057.
25. Ballas SK, Barton FB, Waclawiw MA, Swerdlow P, Eckman JR, Pegelow CH, Koshiy M, Barton BA, Bonds DR. Hydroxyurea and sickle cell anemia: effect on quality of life. Health Qual Life Outcomes BMC. 2006. https://doi.org/10.1186/1477-7525-4-59.
26. Dampier C, LeBeau P, Rhee S, et al. Health-related quality of life in adults with sickle cell disease (SCD): a report from the comprehensive sickle cell centers clinical trial consortium. Am J Hematol. 2011;86:203–5.
27. Beverung LM, Strouse JJ, Hulbert ML, Neville K, Inusa B, Fuh B, King A, Meier ER, Casella J, MR DB, Panepinto JA. Health-related quality of life in children with sickle cell anemia: impact of blood transfusion therapy. Am J Hematol. 2015;90(2):159–43. https://doi.org/10.1002/ajh.2387.
28. Thomburg CD, Calatoni A, Panepinto JA. Differences in health related quality of life in children with sickle cell disease receiving hydroxyurea. J Pediatr Hematol Oncol. 2013;33(4):251–4.
29. Tshilolo L, Tomkinson G, Williams TN, Bridgau S, Olupot-Olupot P, Lane A, Aygun B, Stuber SE, Latham TS, McGann PT, Ware RE. Hydroxyurea for children with Sickle cell anemia in Sub-Saharan Africa. N Engl J Med. 2019;380(2):121–31.
30. Sheriff M, Badawy LB, Cai S, Alexis A. Thompson Association between Participants’ characteristics, patient-reported outcomes, and clinical outcomes in youth with sickle cell disease. BioMed Res Int. 2018. https://doi.org/10.1155/2018/8296139.
31. Badawy SM, Thompson AA, Liem R. Beliefs about hydroxyurea in youth with sickle cell disease. Hemat Oncol Stem Cell Ther. 2018. https://doi.org/10.1016/j.hemonc.2018.01.001.
32. McClitch DK, Penberthy LT, Bovbjerg VE, Roberts JD, Aisiku IP, Levenson JL, Roseff SD, Smith WR. Health related quality of life in sickle cell patients: the PISCES project. Health Qual Life Outcomes. 2005;3(1):50.
33. Bravo AC. Información para pediatras vacunas en el niño con anemia constitucional, 2010.
34. Desai G, Dave KK, Banerjee S, Babaria P, Gupta R. Initial outcomes of a comprehensive care model for sickle cell disease among a tribal population in rural western India. Int J Commun Med Public Health. 2016. https://doi.org/10.18203/2394-6040/ijcmph20161399.